Supriya Lifescience reports Q1 FY27 results with Revenue growing by 30.8% YoY
Supriya Lifescience Ltd., a global cGMP-compliant manufacturer specializing in APIs across various therapeutic segments including anti-histamine, vitamin, and anti-asthmatic products, reported its unaudited financial results for the quarter ended June 30, 2026. The company has a presence in over 120 countries globally.The Q1 FY27 results showed significant revenue growth but also highlighted shifts in profitability metrics compared to Q1 FY26.Key Consolidated Financial Highlights
Supriya Lifescience saw its revenues rise substantially, although the Profit After Tax (PAT) metric decreased year-over-year. The company continues to focus on expanding its...